Key Highlights
- April deliveries from Tesla’s Shanghai facility reached 79,478 vehicles, representing a 36% annual increase
- Month-over-month figures showed a 7.2% decline from March’s performance
- China’s Full Self-Driving regulatory clearance timeline has shifted to Q3 from the initial Q1 projection
- Company insiders liquidated more than 80,000 shares valued at approximately $30.8 million across the last quarter
- Wall Street consensus remains at “Hold” with analysts setting a $398.42 average price objective
Tesla’s Shanghai manufacturing operations produced strong year-over-year results in April, with deliveries climbing 36% compared to the same period twelve months earlier. This performance extends the company’s growth trajectory to six consecutive months of annual gains. The 79,478 vehicles delivered include both domestic Chinese sales and international shipments to European and other global markets.
While sequential monthly data showed an 7.2% reduction from March’s 85,670-unit output, the annual perspective reveals continued strength for the electric vehicle manufacturer.
TSLA began Thursday trading at $398.75, representing approximately a 2.4% intraday increase. The equity trades within a 52-week band spanning $271.00 to $498.83, with the company maintaining a $1.50 trillion market capitalization.
Tesla has faced significant headwinds in the Chinese market over the preceding twelve months. The manufacturer experienced nearly 50% erosion of its European market position throughout 2025, while domestic Chinese competitors offering lower-priced alternatives maintained consistent competitive pressure.
April’s delivery figures indicate potential market stabilization. European demand also showed improvement across multiple countries last month, with Sweden, France, and Denmark all reporting increased sales activity.
Battery-electric vehicle demand in Europe received support from elevated petroleum prices connected to geopolitical tensions involving the United States and Iran.
Regulatory Timeline for Autonomous Technology Extends
Full Self-Driving regulatory approval represents a significant factor in Tesla’s Chinese market strategy. The company currently anticipates receiving complete FSD authorization within Q3, representing a delay from the originally projected Q1 timeframe.
CFO Vaibhav Taneja addressed the timeline adjustment during Tesla’s April quarterly earnings presentation. FSD capability holds particular importance for attracting premium-segment purchasers in the Chinese market.
European regulatory authorities have demonstrated cautious attitudes toward the autonomous driving technology, based on correspondence examined by Reuters.
Tesla is developing a more affordable compact SUV specifically for Chinese production to maintain competitive positioning. This strategic initiative responds directly to the substantial volume of budget-friendly vehicles from local manufacturers.
China’s overall new energy vehicle retail sales totaled 1.22 million units during April, reflecting 7% annual growth according to the China Passenger Car Association.
BYD, Tesla’s primary Chinese competitor, recorded annual sales declining 15% in April to 314,100 units.
Executive Share Activity and Wall Street Perspectives
Tesla’s first-quarter financial performance showed earnings per share of $0.41, surpassing the $0.39 analyst consensus. Revenue totaled $22.39 billion, slightly trailing the $22.96 billion projected figure.
Revenue increased 15.8% on an annual basis. The comparable Q1 2025 period produced $0.27 in earnings per share.
Company directors have recently reduced equity positions. Director Kathleen Wilson-Thompson divested 26,409 shares on April 30 at an average execution price of $378.11, generating proceeds approaching $10 million. This transaction reduced her holdings by 35.3%.
The trailing 90-day period saw insider sales totaling 80,213 shares with combined proceeds of roughly $30.85 million.
Institutional investors continue adjusting positions. Gateway Investment Advisers expanded its Tesla allocation by 0.5% during Q4, purchasing 2,279 additional shares to establish a 498,845-share position valued at approximately $224.3 million.
Wall Street research coverage presents varied perspectives. Among 41 analysts tracking the stock, 19 maintain Buy recommendations, 17 assign Hold ratings, and 5 rate it a Sell. The consensus price target stands at $398.42.
Truist Financial lowered its price objective from $438 to $400 while maintaining a Hold stance on April 2. Bank of America continues with a Buy rating and $460 target price.
